Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

If the European Commission decides to grant sales of the medicine, it will be the first Alzheimer's medicine available in the ...

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...